Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
This Menlo Park biotech specializing in antibody therapies saw a notable insider sale following a year of rapid gains in its share price.
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Overview
Arjun Agarwal, Senior Vice President of Finance, reported the sale of 10,290 shares of Oruka Therapeutics (NASDAQ:ORKA) on May 18, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average reported price ($59.07). Post-transaction value based on May 18 closing price ($58.34).
Details
Note: 1-year performance calculated using May 18, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
